The Role of Ganoderma lucidum Uptake on Some Hematological and Immunological Response in Patients with Coronavirus (COVID-19)

Abstract

Miqdam M. Obaid AL-jumaili, Fahad K. Y. Al-dulaimi, Mohammed A. Ajeel

At the end of 2019, the novel coronavirus was discovered to cause pneumonia in Wuhan city in the Hubei Province, China. Later it has caused significant worldwide crises due to its fast transmission between humans, causing a widespread pandemic around the world. 150 patients with COVID-19 were collected from Shirqat hospital, their ages were between 35-55 years. The patients were divided into four groups. as follows: (1) The healthy control group: normal apparently healthy individuals, (2) G. lucidum group: Healthy individuals received G. lucidum orally, (3) COVID-19 Patients: patients infected with COVID-19, (4) Human convalescent plasma: this group treated Human convalescent plasma for intravenous injection, and (5) Patients COVID-19+ G. lucidum group: this group after infection and treated with G. lucidum, (6) COVID-19 Patients + Human convalescent plasma: this group treated with Human convalescent plasma for intravenous injection. The immunoglobulin (IgG and IgM) were positive in Patients with the COVID-19 group, whereas (IgG) only was positive in Patients COVID-19+G.lucidum and Patients COVID-19+ Human convalescent. The IgM was negative in Patients with COVID-19+G.lucidum and Patients with COVID-19+ Human convalescent groups. The result found that there was a significant change between the study groups (p<0.05) in total white blood cells, there was a less significant increase in G. lucidum group compared with control group. The lymphocyte was significantly decrease for patients with COVID-19 group compared with control group, while significant increase were seen in G. lucidum group and Human convalescent plasma compared with control group and the patients with COVID-19 + G.lucidum group results showed a significant increase compared with patients COVID-19 group.The result showed a significant decrease (p<0.05) in Patients with COVID-19 group of Hb, PCV, RBCs, and Platelet compared with the control group and G.lucidum group, while there was no significant change in the G.lucidum group and Human convalescent plasma group compared with the control group. Convalescent plasma together with the hyperimmune immunoglobulin have appositive effects on treating the COVID-19, as well as the G. lucidum has a great significant role in reducing the COVID-19 malicious effect on the studied hematological parameters. G. lucidum can be used to help in the treatment of COVID-19 infections.